HKSE · 2877.HK
China Shineway Pharmaceutical Group Limited
HK$7.51+HK$0.23 (+3.09%)
China Shineway Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.32% below the high.
Loading market information…
OTC · ENZB · USD
Stock price, dividends, earnings
Quote as of Aug 20, 2025, 12:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Enzo Biochem, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Enzo Biochem, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Enzo Biochem, Inc. operates as an integrated entity encompassing diagnostics, clinical laboratory services, and life sciences. The company is dedicated to developing, manufacturing, and commercializing diagnostic and research products, fundamentally rooted in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division focuses on creating, producing, and distributing essential products and tools for clients engaged in clinical research, pharmaceutical development, and broader bioscience investigations. Its extensive portfolio comprises proteins, antibodies, peptides, small molecules, labeling probes, dyes, and various kits. These offerings empower life science researchers in areas such as target identification and validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also serves scientific experts researching a wide array of health issues, including cancer, cardiovascular disorders, neurological diseases, diabetes and obesity, endocrine imbalances, infectious and autoimmune conditions, hepatotoxicity, and renal injury. Through its Clinical Laboratory Services segment, Enzo Biochem provides a spectrum of molecular and other clinical laboratory tests and procedures. These are utilized in routine patient care by medical professionals to aid in establishing or corroborating diagnoses, monitoring treatment efficacy or medication levels, and uncovering previously undiagnosed conditions. This segment operates a full-scale clinical laboratory in Farmingdale, New York, supported by a network of 30 patient service centers throughout New York and New Jersey. Furthermore, it manages specialized "STAT" or rapid response laboratories in New York City and Connecticut, along with a complete phlebotomy center and an internal logistics department. The Therapeutics segment is committed to devising innovative solutions for gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem promotes its products and services globally through a dedicated direct sales force and an established network of distributors. The company was founded in 1976 and maintains its corporate headquarters in New York, New York.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:03 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$7.51+HK$0.23 (+3.09%)
China Shineway Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.32% below the high.
$1.96+$0.00 (0.0%)
MedPeer,Inc.’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
$0.11-$0.01 (-9.69%)
Small Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.36% below the high.
$5.73$0.00 (0.0%)
Alpha Cognition Inc.: Healthcare · Biotechnology.
CA$0.45-CA$0.01 (-2.17%)
Rocket Doctor AI Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.08% below the high.
$0.03$0.00 (0.0%)
Pharmaxis Ltd: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.17$0.00 (0.0%)
IntelGenx Technologies Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$3.75+$0.01 (+0.27%)
PharmChem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.78% below the high.
